FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus.

[1] The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus.

In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.

[2][3] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.